An observational study in Atopic Dermatitis, sponsored by EHL Bio Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-02-15.
Sponsored by EHL Bio Co., Ltd. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Dermatitis, Atopic with a site in Korea, Republic of — 7 open to participants now, 18 under way, 7 of them phase 3. Dermatitis, Atopic · Korea, Republic of.
Among the 83 studies in Dermatitis, Atopic with a site in Korea, Republic of, this one is the 12th largest by enrollment of the 12 observational ones that give a count, is one of 3 that started in 2017, is one of 12 observational ones, and was the 22nd registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →7 of the 83 studies in Dermatitis, Atopic with a site in Korea, Republic of are open now. Recruiting first, the newest first:
EHL Bio Co., Ltd. · Sites in Korea, Republic of
Ages 19–70
HK inno.N Corporation · Sites in Korea, Republic of
Ages 19+
Novartis Pharmaceuticals · Sites in Korea, Republic of, United States, Argentina and 14 more countries
Ages 18–100
LEO Pharma · Sites in Korea, Republic of, United States, Belgium and 10 more countries
Ages 6 mo–11 yrs
Pfizer · Sites in Korea, Republic of
Ages 12+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 19 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 25 · Phase 3 39 · Phase 4 1
First in 2007; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11 is below the median of 150 across 283 observational studies indexed under Dermatitis, Atopic.
Median enrollment 234 across the 71 interventional studies, 101 across the 12 observational. Of the 58 that completed or were terminated, 32 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
74 of 83 have an industry lead sponsor. The 10 most frequent:
EHL Bio Co., Ltd. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
EHL Bio Co., Ltd. has 4 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
5 of the studies in Dermatitis, Atopic with a site in Korea, Republic of that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06389136Phase 3AbbVieA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | 2026-11 |
| NCT06241118Phase 3SanofiA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor | 2027-09-30 |
| NCT06718101AbbVieA Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis | 2027-05 |
| NCT07217015Kymera Therapeutics, Inc.A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis | 2027-06 |
| NCT05391061PfizerA Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis | 2027-11-22 |
Add all 5 to your calendar (.ics) → With an account.
Among the 83 studies in Dermatitis, Atopic with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate safety in subjects with over moderately subacute and chronic atopic dermatitis after an intravenous injection of ADSTEM Inj. Since this is an observational study of patients participated in Phase 1 clinical trials, no drug is administered in this study.
Participants will be followed-up for adverse events on each visit. Visits will be on 6, 12, 18, 24, 30, 36, 48, 60months after treatment of ADSTEM Inj.
Time perspective is both retrospective and prospective.
Patients who participated in Phase I clinical trials
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants in Phase I clinical trials treated with ADSTEM Inj.
Drug: ADSTEM Inj.
1. ADSTEM Inj. 1.0x10\^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial. 2. ADSTEM Inj. 3.0x10\^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial.
Tumor formation
The number of subjects with treatment-related tumor formation
Time frame: 60months after treatment of ADSTEM Inj.
Adverse events
The number of subjects with treatment-related adverse events
Time frame: 60months after treatment of ADSTEM Inj.
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2017 to primary completion in Aug 2022, 58 months.
Of 74 industry-sponsored observational studies under Dermatitis, Atopic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 84. This study's 58 months is above that.
Counting every sponsor, half of 171 studies reached it within 35 months; a quarter within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
EHL Bio Co., Ltd.